Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.51 |
| ▸ | RXRG | P48443 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020080 | 0.88 | RXRA (0.57) | HTR2CSLC6A4HTR2BRXRARXRB | |
| SCHEMBL4883033 | 0.86 | LRRK2 (0.51) | HTR2CSLC6A4HTR2BRXRARXRB | |
| SCHEMBL24314204 | 0.84 | FFAR1 (0.52) | HTR2CSLC6A4HTR2BFFAR1RXRA | |
| SCHEMBL29469922 | 0.84 | FFAR1 (0.52) | HTR2CSLC6A4HTR2BFFAR1RXRA | |
| SCHEMBL18703359 | 0.83 | MRGPRX4 (0.61) | HTR2CSLC6A4HTR2BFFAR1RXRA | |
| SCHEMBL1331639 | 0.83 | HTR2C (0.58) | HTR2CSLC6A4HTR2BRXRARXRB | |
| SCHEMBL1332170 | 0.81 | SLC6A4 (0.56) | HTR2CSLC6A4HTR2BRXRARXRB | |
| SCHEMBL30427926 | 0.81 | MRGPRX4 (0.72) | MRGPRX4 | |
| SCHEMBL6080280 | 0.81 | MRGPRX4 (0.57) | HTR2CSLC6A4HTR2BRXRARXRB | |
| SCHEMBL5730837 | 0.81 | HTR2C (0.60) | HTR2CSLC6A4HTR2BRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20080234335-A1 | Cyclohexene Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1670756-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670764-A1 | CYCLOHEXENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| CN-1659131-A | (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LTD (GB) | 2005-08-24 | — | — | CN | disclosed |
| EP-1556330-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005037794-A1 | CYCLOHEXENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037786-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| EP-1492757-A1 | (2-((2-ALKOXY)-PHENYL)-CYCLOPENT-1-ENYL) AROMATIC CARBO- AND HETEROCYCLIC CARBOXYLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004039753-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003084917-A1 | (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | HTR2C 480/4885SLC6A4 3221/4885HTR2B 383/4885 |
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | HTR2C 3002/4885SLC6A4 4647/4885HTR2B 906/4885 |
| US-20080234335-A1 | Cyclohexene Compounds | C1R, CYP1B1, CYP2C9 | HTR2C 1275/4885SLC6A4 4442/4885HTR2B 157/4885 |
| US-20060235057-A1 | Phenyl compounds | RXRB, CYP2C9, RXFP1 | HTR2C 1327/4885SLC6A4 2990/4885HTR2B 127/4885 |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | HTR2C 469/4885SLC6A4 3796/4885HTR2B 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.